Mankind Pharma profit rises 39% in second quarter

Mankind Pharma reported a 39% increase in consolidated net profit for the September quarter, rising to Rs 711 crore from Rs 512 crore in the previous year. The company's revenue from operations grew by 17.3% to Rs 4,338 crore.

Growth was driven by strong demand for chronic therapies, including diabetes and cardiac treatments. Domestic revenue rose 15.9%, supported by double-digit growth in the Mankind and BSV specialty businesses, while international revenue increased by 33%. The company's operating margin improved to approximately 27%, up from 25% a year ago.

In its international operations, Mankind introduced one new product in the US, bringing its total US launches to 50. Additionally, the company recently acquired Armed Cell Therapeutics to enter the CAR-T therapy market. The board also approved the merger of two wholly owned subsidiaries, Prolijune Lifesciences and Pavi Buildwell.